18 Jun 2007 - At its Annual General Assembly in Brussels, EuropaBio members elected Steen Riisgaard, President and CEO, Novozymes A/S to chair the association for the next two years, he succeeds Hans Kast, President and CEO, BASF Plant Science Holding AG, who has completed his mandate but will stay on as a Board Member.
EuropaBio's membership grew further with the General Assembly voting in 15 new member companies and associate members. This brings the association's membership to a total of 81 companies, 6 associate members and 6 bioregions as well as 25 national biotechnology associations representing some 1800 biotechnology companies from as diverse backgrounds as the pharmaceutical industry, seed industry, fuel companies, vaccine developers - what they all have in common is that they are involved in research and development, testing, manufacturing and distribution of biotechnology products.
The new chair, Steen Riisgaard, said that he is looking forward to chairing the biotech association as biotechnology enters a crucial phase of development and is increasingly a motor of innovation in several industries. Synergies are needed with many sectors that can use biotechnology. "The key word is partnership. We need partnerships with hospitals, the pharmaceutical sector, diagnostics companies, patient groups, vaccine manufacturers, chemical industries, the energy sector, European farmers and many, many more."
 |
www.bionity.com/news/e/65485 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/65485 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |